Article: BDSI Secures $7 Million Financing Commitment For Development of BEMA(TM) Fentanyl; Funding Targeted for Phase III Trials of Cancer Pain Medication.

Article: BioDelivery Sciences Retains Addison Whitney as Brand Development ...
Business Wire;  February 2, 2006 ;     700+ words ... ... Addison Whitney, Inc. to develop the brand identity and brand strategy for its BEMA(TM) drug delivery technology and BEMA(TM) Fentanyl, the company's lead BEMA(TM) formulation. Due to the nature of the BEMA(TM) technology and the scope ...

Article: ONSOLIS(TM) (BEMA(TM) Fentanyl) Data to be ...
Business Wire;  October 20, 2008 ;     700+ words ... ... TM]) (formerly referred to as BEMA([TM]) Fentanyl) will be presented ... profile. These data include: "BEMA([TM]) Fentanyl Shows a Favorable Pharmacokinetic ... from 9:00 to 11:00 a.m. "BEMA([TM]) Fentanyl Offers High Absolute ...

Article: BEMA(TM) Fentanyl Demonstrates Substantial ...
Business Wire;  May 7, 2007 ;     700+ words ... ... fentanyl from both single and multiple BEMA(TM) Fentanyl discs, as well as oral ... delivery system) of fentanyl from the BEMA(TM) disc was more than 70, with 50 ... statistically significant results with BEMA(TM) Fentanyl in treating cancer patients ...

Article: BioDelivery Sciences Files IND for BEMA(TM) LA, a ...
Business Wire;  January 6, 2006 ;     700+ words ... ... Administration (FDA) for the company's BEMA(TM) Long Acting Analgesic (LA) product. If and when approved by FDA, BEMA(TM) LA is intended to meet the need ... treatment of moderate to severe pain. BEMA(TM) LA will be formulated using BDSI ...

Article: BDSI Receives $30 Million Upfront Payment Under ...
Business Wire;  September 14, 2007 ;     700+ words ... ... exclusive license agreement for the commercialization of BEMA(TM) Fentanyl in the U.S., Canada and Mexico. While ... developing our other pipeline products." About BEMA(TM) Fentanyl BEMA(TM) Fentanyl consists of a small, dissolvable, polymer ...

Article: BDSI Announces Purchase of Non-U.S. BEMA(TM) ...
Business Wire;  August 3, 2006 ;     700+ words ... ... of the non-U.S. rights to the BEMA(TM) drug delivery technology, including ... this transaction, BDSI had licensed BEMA(TM) from QLT USA on a worldwide, exclusive ... basis. Besides the rights to the BEMA(TM) technology outside of the U.S ...

Article: BioDelivery Sciences International and MEDA AB Announce European ...
Business Wire;  August 3, 2006 ;     700+ words ... ... develop and commercialize BDSI's flagship BEMA(TM) Fentanyl product in Europe. BEMA(TM) Fentanyl is a Phase III product being developed ... European development and commercialization of BEMA(TM) Fentanyl, in exchange for an upfront fee ...